Abstract
Objectives
The diagnosis of sepsis is challenging, the need for sensitive and specific diagnostic and prognostic biomarkers has not been met. Soluble CD25 (sCD25) is a readily available biomarker reported to represent the severity of the disease. This study aimed to assess the association between sCD25 and mortality in patients with sepsis.
Methods
In total, 329 adult patients with sepsis were screened through a prospective, observational study. We investigated the severity scores and sCD25 levels at admission to the intensive care unit (ICU), defined by sepsis (sepsis-3). The prognostic value of sCD25 was assessed using receiver operating characteristic (ROC) curves and binary logistic regression models in predicting unfavourable outcome. The correlations between variables and severity of disease were analysed by Spearman correlation tests.
Results
After entering the ICU, the sCD25 level and sequential organ failure assessment (SOFA) score were significantly higher in nonsurvivors than in survivors. The prognostic values estimated by the ROC curves were 0.678 for sCD25 and 0.945 for SOFA score at ICU admission. sCD25 had a modest ability to predict poor outcome. Logistic regression showed that increased levels of sCD25 were independently associated with unfavourable outcome. Spearman correlation tests showed that sCD25 levels were positively correlated with disease severity.
Conclusions
In sepsis patients, increased sCD25 levels were independently associated with poor clinical outcomes. Further research is needed to improve the understanding of the pathophysiology of this relationship.
Acknowledgments
We thank the Emergency Department of Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine for its comprehensive support for this study.
-
Research funding: None declared.
-
Author contribution: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.
-
Competing interests: Authors state no conflict of interest.
-
Informed consent: Informed consent was obtained from all individuals included in this study.
-
Ethical approval: The study was approved by the Ethics Committee of Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine and was carried out in accordance with the Declaration of Helsinki. All data were anonymized.
References
1. Singer, M, Deutschman, CS, Seymour, CW, Shankar-Hari, M, Annane, D, Bauer, M, et al.. The Third international Consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 2016;315:801–10, https://doi.org/10.1001/jama.2016.0287.Search in Google Scholar
2. Cecconi, M, Evans, L, Levy, M, Rhodes, A. Sepsis and septic shock. Lancet 2018;392:75–87, https://doi.org/10.1016/s0140-6736(18)30696-2.Search in Google Scholar
3. Dombrovskiy, VY, Martin, AA, Sunderram, J, Paz, HL. Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003. Crit Care Med 2007;35:1244–50, https://doi.org/10.1097/01.ccm.0000261890.41311.e9.Search in Google Scholar
4. Remick, DG. Pathophysiology of sepsis. Am J Pathol 2007;170:1435–44, https://doi.org/10.2353/ajpath.2007.060872.Search in Google Scholar PubMed PubMed Central
5. Monneret, G, Venet, F, Pachot, A, Lepape, A. Monitoring immune dysfunctions in the septic patient: a new skin for the old ceremony. Mol Med 2008;14:64–78, https://doi.org/10.2119/2007-00102.Monneret.Search in Google Scholar PubMed PubMed Central
6. Becker, KL, Snider, R, Nylen, ES. Procalcitonin assay in systemic inflammation, infection, and sepsis: clinical utility and limitations. Crit Care Med 2008;36:941–52, https://doi.org/10.1097/ccm.0b013e318165babb.Search in Google Scholar
7. Maruna, P, Nedelnikova, K, Gurlich, R. Physiology and genetics of procalcitonin. Physiol Res 2000;49:S57–61.Search in Google Scholar
8. Povoa, P. C-reactive protein: a valuable marker of sepsis. Intensive Care Med 2002;28:235–43, https://doi.org/10.1007/s00134-002-1209-6.Search in Google Scholar PubMed
9. Spapen, HD, Hachimi-Idrissi, S, Corne, L, Huyghens, LP. Diagnostic markers of sepsis in the emergency department. Acta Clin Belg 2006;61:138–42, https://doi.org/10.1179/acb.2006.022.Search in Google Scholar PubMed
10. Pierrakos, C, Vincent, JL. Sepsis biomarkers: a review. Crit Care 2010;14:R15, https://doi.org/10.1186/cc8872.Search in Google Scholar PubMed PubMed Central
11. Jensen, JU, Hein, L, Lundgren, B, Bestle, MH, Mohr, TT, Andersen, MH, et al.. Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: a randomized trial. Crit Care Med 2011;39:2048–58, https://doi.org/10.1097/ccm.0b013e31821e8791.Search in Google Scholar PubMed
12. Bouadma, L, Luyt, CE, Tubach, F, Cracco, C, Alvarez, A, Schwebel, C, et al.. Use of procalcitonin to reduce patients’ exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 2010;375:463–74, https://doi.org/10.1016/s0140-6736(09)61879-1.Search in Google Scholar
13. Cohen, J. The immunopathogenesis of sepsis. Nature 2002;420:885–91, https://doi.org/10.1038/nature01326.Search in Google Scholar PubMed
14. Hotchkiss, RS, Karl, IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003;348:138–50, https://doi.org/10.1056/nejmra021333.Search in Google Scholar PubMed
15. Rubin, LA, Kurman, CC, Fritz, ME, Biddison, WE, Boutin, B, Yarchoan, R, et al.. Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J Immunol 1985;135:3172–7.10.4049/jimmunol.135.5.3172Search in Google Scholar
16. von Bahr Greenwood, T, Palmkvist-Kaijser, K, Chiang, SC, Tesi, B, Bryceson, YT, Hjelmqvist, H, et al.. Elevated ferritin and soluble CD25 in critically ill patients are associated with parameters of (hyper) inflammation and lymphocyte cytotoxicity. Minerva Anestesiol 2019;85:1289–98. https://doi.org/10.23736/S0375-9393.19.13534-1.Search in Google Scholar PubMed
17. de Guadiana-Romualdo, LG, Berger, M, Jiménez-Santos, E, Rebollo-Acebes, S, Jiménez-Sánchez, R, Esteban-Torrella, P, et al.. Pancreatic stone protein and soluble CD25 for infection and sepsis in an emergency department. Eur J Clin Invest 2017;47:297–304. https://doi.org/10.1111/eci.12732.Search in Google Scholar PubMed
18. Saito, K, Wagatsuma, T, Toyama, H, Ejima, Y, Hoshi, K, Shibusawa, M, et al.. Sepsis is characterized by the increases in percentages of circulating CD4+CD25+ regulatory T cells and plasma levels of soluble CD25. Tohoku J Exp Med 2008;216:61–8, https://doi.org/10.1620/tjem.216.61.Search in Google Scholar PubMed
19. Hosomi, S, Yamagami, H, Itani, S, Yukawa, T, Otani, K, Nagami, Y, et al.. Sepsis markers soluble IL-2 receptor and soluble CD14 subtype as potential biomarkers for complete mucosal healing in patients with inflammatory Bowel disease. J Crohns Colitis 2018;12:87–95. https://doi.org/10.1093/ecco-jcc/jjx124.Search in Google Scholar PubMed
20. Garcia de Guadiana-Romualdo, L, Berger, M, Jimenez-Santos, E, Rebollo-Acebes, S, Jimenez-Sanchez, R, Esteban-Torrella, P, et al.. Pancreatic stone protein and soluble CD25 for infection and sepsis in an emergency department. Eur J Clin Invest 2017;47:297–304, https://doi.org/10.1111/eci.12732.Search in Google Scholar
21. Gaieski, DF, Edwards, JM, Kallan, MJ, Carr, BG. Benchmarking the incidence and mortality of severe sepsis in the United States. Crit Care Med 2013;41:1167–74, https://doi.org/10.1097/ccm.0b013e31827c09f8.Search in Google Scholar
22. Rudd, KE, Kissoon, N, Limmathurotsakul, D, Bory, S, Mutahunga, B, Seymour, CW, et al.. The global burden of sepsis: barriers and potential solutions. Crit Care 2018;22:232, https://doi.org/10.1186/s13054-018-2157-z.Search in Google Scholar PubMed PubMed Central
23. Harrison, DA, Welch, CA, Eddleston, JM. The epidemiology of severe sepsis in England, Wales and Northern Ireland, 1996 to 2004: secondary analysis of a high quality clinical database, the ICNARC Case Mix Programme Database. Crit Care 2006;10:R42, https://doi.org/10.1186/cc4854.Search in Google Scholar
24. Garcia-Obregon, S, Azkargorta, M, Seijas, I, Pilar-Orive, J, Borrego, F, Elortza, F, et al.. Identification of a panel of serum protein markers in early stage of sepsis and its validation in a cohort of patients. J Microbiol Immunol Infect 2018;51:465–72, https://doi.org/10.1016/j.jmii.2016.12.002.Search in Google Scholar
25. Llewelyn, MJ, Berger, M, Gregory, M, Ramaiah, R, Taylor, AL, Curdt, I, et al.. Sepsis biomarkers in unselected patients on admission to intensive or high-dependency care. Crit Care 2013;17:R60, https://doi.org/10.1186/cc12588.Search in Google Scholar
26. Matera, G, Puccio, R, Giancotti, A, Quirino, A, Pulicari, MC, Zicca, E, et al.. Impact of interleukin-10, soluble CD25 and interferon-gamma on the prognosis and early diagnosis of bacteremic systemic inflammatory response syndrome: a prospective observational study. Crit Care 2013;17:R64, https://doi.org/10.1186/cc12596.Search in Google Scholar
27. Boeck, L, Graf, R, Eggimann, P, Pargger, H, Raptis, DA, Smyrnios, N, et al.. Pancreatic stone protein: a marker of organ failure and outcome in ventilator-associated pneumonia. Chest 2011;140:925–32, https://doi.org/10.1378/chest.11-0018.Search in Google Scholar
28. Peteiro-Cartelle, FJ, Alvarez-Jorge, A. Dynamic profiles of interleukin-6 and the soluble form of CD25 in burned patients. Burns 1999;25:487–91, https://doi.org/10.1016/s0305-4179(99)00032-7.Search in Google Scholar
© 2022 Walter de Gruyter GmbH, Berlin/Boston
